Floatz logo

Psma-Hbed-Cc

Castration-Resistant Prostate Carcinoma

Fred Hutchinson Cancer CenterradiopharmaceuticalPhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
73/ 100

Competitive context

58 Active assets in the Castration-Resistant Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
PREDNISONE TABLETS
Janssen Research & Development, LLC
Phase 4BB
Abiraterone Acetate
Alliance for Clinical Trials in Oncology
Phase 4BB
Cyclophosphamide
Zhejiang University
Phase 2BB
TESTOSTERONE CIPIONATE
Roswell Park Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Psma-Hbed-Cc is also rated in:

Metastatic Prostate CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
Prostate AdenocarcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →